This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: C09 (C09.0 tonsillar fossa, C09.1 tonsillar pillar (anterior), C09.8 overlapping sites, C09.9 unspecified) | Special Copayment Reduction: V193 (copayment 5% for care of the relevant diagnosis for 5 years from the date of cancer patient registration) |
| B. Synonyms | Tonsil cancer, palatine tonsil cancer, tonsillar fossa cancer; Tonsillar carcinoma, Palatine tonsil squamous cell carcinoma, Tonsil cancer, Oropharyngeal tonsil cancer |
| C. Adult onset | Likelihood of first onset in adulthood very high — mainly diagnosed in the 40s–70s; HPV+ tonsil cancer is increasing in relatively younger nonsmoking men in their 45–60s |
| 1. History | Recognized as the most common subtype of oropharyngeal cancer; HPV–tonsil cancer association established in the 2000s (Gillison et al.); separate HPV+ staging system in AJCC 8th edition |
| 2. Causes | HPV-16 (now the main cause, 60–80% in North America and the West), smoking and alcohol (main causes of HPV– tonsil cancer), immunosuppression, persistent oral HPV infection |
| 3. Genetics | HPV+: E6/E7→p53·Rb inactivation·p16 overexpression·PIK3CA·TRAF3; HPV–: TP53·CDKN2A·FAT1·NOTCH1·CASP8; EGFR overexpression |
| 4. General epidemiology | Most common subtype of oropharyngeal cancer, increasing worldwide, a rising site among head and neck cancers in Korea as well, male predominance (3:1), 40s–70s |
| 5. Pathophysiology | HPV infection of tonsillar crypt mucosa→E6/E7 oncoprotein expression; EGFR·PI3K·Wnt·Notch pathways; abundant tumor-infiltrating lymphocytes (TIL) |
| 6. Symptoms | Sore throat·odynophagia·otalgia (referred pain)·halitosis·unilateral tonsillar enlargement; a neck mass is often the first symptom (large neck metastasis from a small primary tumor) |
| 7. Signs | Unilateral tonsillar enlargement·ulceration·mass, peritonsillar invasion, cystic level II neck lymph nodes (characteristic of HPV+), trismus |
| 8. Screening | Visual examination of the oral cavity and pharynx, otolaryngologic endoscopic examination, oral HPV testing (research use), HPV vaccination (prevention) |
| 9. Diagnosis | CT·MRI·PET-CT, endoscopic biopsy, p16 immunohistochemistry·HPV ISH, separate AJCC 8th edition TNM staging for HPV-positive/negative |
| 10. Treatment | Concurrent chemoradiotherapy (CRT), TORS+neck dissection, IMRT (66–70 Gy), HPV+ de-escalation clinical trials, pembrolizumab·nivolumab |
| 11. Prognosis | HPV+ 5-year survival 80–90%, HPV– 40–50%; cystic lymph node metastasis is not an adverse prognostic factor; success rate of salvage treatment after recurrence is also higher in HPV+ |
| 12. Prevention | 9-valent HPV vaccine (top priority), smoking cessation and reduced drinking, regular otolaryngology checkups, oral sexual hygiene education |
| 13. References | Gillison ML et al. Epidemiology of HPV-Positive Head and Neck SCC. J Clin Oncol. 2015 ... and 9 other papers |
Tonsil cancer (malignant neoplasm of the palatine tonsil) is the most common subtype of oropharyngeal cancer and has historically been regarded as a head and neck squamous cell carcinoma related to smoking and alcohol. However, since the 2000s, with the establishment of the association between HPV (human papillomavirus) and tonsil cancer, a fundamental paradigm shift has occurred across epidemiology, pathogenesis and prognosis.
The tonsils are part of Waldeyer's lymphatic ring and have abundant lymphoid tissue and a unique mucosal structure called tonsillar crypts. This crypt structure provides an anatomic feature that allows HPV easy access to the basal epithelial cells, making it a preferred site of HPV infection.
The 2000 study by Gillison et al. was the first to systematically demonstrate that HPV-16 infection is an independent risk factor for oropharyngeal squamous cell carcinoma. Numerous epidemiologic studies since then have confirmed a sharp increase in the incidence of HPV-positive oropharyngeal cancer (especially tonsil cancer) in North America and Western Europe. HPV was revealed as the cause of the paradoxical phenomenon of rising oropharyngeal cancer despite declining smoking.
In 2017, the AJCC 8th edition introduced separate TNM staging classifications for HPV-positive and HPV-negative oropharyngeal cancer, formally recognizing the biologic and prognostic differences between these two subtypes. In the 21st century, de-escalation clinical trials exploiting the excellent treatment response of HPV-positive tonsil cancer are actively under way. In Korea as well, an increase in tonsil cancer among head and neck cancers and a rising proportion of HPV positivity have been reported.
Human papillomavirus (HPV-16) is now the most important cause of tonsil cancer; in the West, 60–80% of tonsil cancers, and up to 90% in some countries, are HPV-related. In Korea as well, the proportion of HPV-positive oropharyngeal cancer is increasing, though still lower than in the West. Oral HPV-16 infection increases the risk of tonsil cancer more than 15-fold and is transmitted through sexual contact (especially oral sex). An increasing number of oral sex partners correlates with an increased risk of HPV-positive tonsil cancer.
In HPV-negative tonsil cancer, smoking and alcohol are the main risk factors. Tobacco carcinogens (PAH, nitrosamines) act directly on the tonsillar mucosa, and alcohol promotes a carcinogenic environment. Combined exposure to smoking and alcohol has a synergistic carcinogenic effect.
Immunosuppressant use after organ transplantation and immunodeficiency due to HIV infection increase persistent HPV infection and the risk of tonsil cancer. Poor oral hygiene is also an ancillary risk factor.
When HPV-16 infects the basal cells of the tonsillar crypts and the viral DNA integrates into the host genome, the E6 and E7 oncoproteins are overexpressed. E6 degrades p53, disabling its tumor suppressor function, and E7 binds the Rb protein, releasing the G1/S cell cycle checkpoint. As a result, p16 (CDKN2A) is reactively overexpressed, so p16 immunohistochemistry is used as a surrogate marker for HPV. In HPV+ tonsil cancer, PIK3CA mutations and TRAF3 deletions are common, and E2F1 amplification is also observed. Overall, HPV+ tumors have more tumor-infiltrating lymphocytes (TIL) and higher immunogenicity than HPV– tumors.
In HPV-negative tonsil cancer, the main mechanism is accumulation of somatic mutations from smoking and alcohol. TP53 (60–80%), CDKN2A, FAT1, NOTCH1, CASP8 and HRAS variants are common. EGFR overexpression is prominent and provides the molecular rationale for cetuximab use.
PD-L1 CPS is used to determine the indication for first-line pembrolizumab. Pembrolizumab alone is used with CPS≥1, and greater clinical benefit is confirmed with CPS≥20. TMB and MMR deficiency are also being studied as predictive markers of immunotherapy response.
Tonsil cancer is the most common subtype of oropharyngeal cancer, and HPV-related oropharyngeal cancer is increasing rapidly worldwide. In the United States, since the 2000s, oropharyngeal cancer (especially tonsil and base of tongue cancer) has become the fastest-growing site among head and neck cancers due to the HPV epidemic. While 70–80% of tonsil cancers in North America and Northern Europe are HPV-positive, this proportion is lower in East Asia.
In Korea as well, tonsil cancer incidence was reported to have risen steeply among head and neck cancers between 1999 and 2012. According to National Cancer Center data, the annual incidence of oropharyngeal cancer (including tonsil) is increasing, and the HPV-positive proportion is also rising. It occurs more often in men than women at a ratio of about 3:1, and the main age of onset is the 40s–70s.
The tonsillar crypts have nonkeratinized squamous epithelium and a reticulated structure, and function to deliver antigens to the lymphoid tissue. This structure gives HPV easy access to the basal epithelial cells, making the tonsil a preferred site of HPV infection. When viral DNA integrates into the host genome after HPV infection, the E6/E7 oncoproteins are persistently expressed, inactivating p53 and Rb function and inducing cell cycle escape and resistance to apoptosis.
HPV+ tonsil cancer is more immunogenic than HPV– tumors, with abundant CD8+ TIL (tumor-infiltrating lymphocytes) and high PD-L1 expression. This underlies its greater sensitivity to immunotherapy and is also the molecular basis for its more favorable prognosis.
The EGFR/RAS/MAPK pathway and the PI3K/AKT/mTOR pathway are central to cell proliferation and survival. In HPV+ tumors, hyperactivation of the PI3K pathway by PIK3CA variants is prominent. The Wnt/β-catenin and Notch pathways also contribute to abnormal differentiation and invasion.
Early symptoms of tonsil cancer are relatively mild and easily confused with ordinary tonsillitis or sore throat. Sore throat, a unilateral foreign body sensation in the pharynx, and discomfort on swallowing are the most common early symptoms. Referred pain to the ear (otalgia, referred otalgia) may occur via the glossopharyngeal nerve (CN IX). Halitosis and enlargement and redness of one tonsil are also early manifestations.
HPV-positive tonsil cancer tends to metastasize early to the cervical lymph nodes even when the primary tumor is small and inconspicuous. As a result, patients often present with a cystic neck mass as the first symptom, and it is sometimes mistaken for cancer of unknown primary. In nonsmoking men in their 40s–60s with cystic cervical lymph node metastasis, HPV-positive tonsil cancer or base of tongue cancer should be strongly suspected.
As the tumor grows, odynophagia, dysphagia, trismus (pterygoid muscle invasion) and limited tongue movement appear. In advanced cancer, weight loss, anorexia and generalized fatigue accompany.
Asymmetric enlargement of one tonsil, an irregular ulcerative mass on the surface, and invasion into peritonsillar tissue are observed. Invasion into the posterior tonsillar pillar and base of the tongue is also checked. The entire tonsillar fossa and oropharynx are examined with flexible endoscopy.
Ipsilateral level II (jugulo-digastric) neck lymph node enlargement is most common. In HPV-positive tonsil cancer, neck lymph nodes with cystic degeneration (cystic cervical lymphadenopathy) characteristically appear. These are seen as cystic densities on ultrasound and CT and can often be misdiagnosed as a branchial cleft cyst. Besides neck levels II and III, metastasis can also occur to retropharyngeal lymph nodes and level V lymph nodes.
CT shows an enhancing tonsillar mass and cystic or noncystic cervical lymph node metastases. MRI is useful for assessing invasion of the lateral pharyngeal wall, posterior pharyngeal wall, parapharyngeal space and skull base. PET-CT is essential for searching for the primary tumor and assessing distant metastasis.
Regular visual examination of the oropharynx, including the tonsils, is key to early detection. Otolaryngologic endoscopy systematically examines the tonsillar mucosa, tonsillar fossa and lateral oropharyngeal wall. Prompt workup is needed when unilateral tonsillar enlargement persists for more than 3 weeks or there is a neck mass not explained by another cause.
There are reports that detection of HPV-16 in oral rinse (gargle) precedes clinical tonsil cancer by several years, so its potential as a future screening tool is under study. However, it is not currently established as a standard clinical screening test.
9-valent HPV vaccination is recommended as a means of preventing tonsil cancer. The preventive effect is greatest when given before sexual debut, and vaccination of both adolescent boys and girls is ideal.
CT (contrast-enhanced): assesses tonsillar tumor size, lateral pharyngeal wall invasion, cervical lymph node metastasis (cystic/noncystic) and distant metastasis. MRI: superior for assessing parapharyngeal space, posterior pharyngeal wall, skull base and perineural invasion. PET-CT: a standard test, even in small primary tonsil cancers (clinical T1-T2), for searching for cervical lymph node metastasis, confirming distant metastasis, and searching for an unknown primary.
Tissue is obtained by tonsil biopsy or fine-needle aspiration cytology (FNAC) of a cervical lymph node. p16 immunohistochemistry (strong, diffuse nuclear and cytoplasmic positivity in ≥70% of tumor cells) is used as a surrogate marker for HPV. Confirmation is by HPV DNA ISH or PCR. In the AJCC 8th edition, separate staging classifications apply to HPV-positive (p16-positive) and HPV-negative tonsil cancer.
The T classification of HPV-positive oropharyngeal cancer is the same, but the N classification is relaxed. It is simplified to N1 (ipsilateral single ≤6 cm), N2 (contralateral or bilateral ≤6 cm) and N3 (>6 cm). The extranodal extension (ENE) criterion is excluded from HPV+ staging. Even with the same neck metastasis status, HPV+ disease is assigned a lower stage, reflecting its more favorable prognosis.
In locally advanced (stage III-IV) tonsil cancer, concurrent chemoradiotherapy (CRT) is the first-line standard treatment. With IMRT/VMAT, 66–70 Gy is prescribed to the primary site and metastatic lymph nodes, 60 Gy to high-risk elective regions, and 54–56 Gy to low-risk elective regions. Cisplatin (100 mg/m², every 3 weeks) is the standard agent for concurrent chemotherapy. In elderly patients or those with reduced renal function, carboplatin or cetuximab is substituted.
Tonsillectomy and neck dissection using transoral robotic surgery (TORS) are performed in early (T1-T2) tonsil cancer. Adjuvant radiotherapy or CRT is given after surgery according to pathologic findings. TORS offers faster recovery and better functional preservation than open surgery.
De-escalation strategies that exploit the excellent treatment response of HPV-positive tonsil cancer to reduce treatment toxicity while maintaining equivalent oncologic outcomes are being actively studied. Approaches such as reduced radiation dose (54–60 Gy), cetuximab instead of cisplatin, and omission of radiotherapy after TORS are in clinical trials (ECOG-3311, ORATOR, HN002, etc.). Currently, de-escalation is recommended only within clinical trials.
Based on KEYNOTE-048, pembrolizumab alone (CPS≥1) or pembrolizumab+cisplatin/carboplatin+5-FU combination is first-line treatment. Based on CheckMate 141, nivolumab is second-line treatment. Cetuximab+EXTREME combination is also a first-line option.
HPV status is the most important prognostic factor in tonsil cancer.
| HPV status | 5-year overall survival rate | Features |
|---|---|---|
| HPV-positive | About 80–90% | Success rate of salvage treatment after recurrence is also high |
| HPV-negative | About 40–50% | Related to smoking and alcohol; poor prognosis on recurrence |
Xerostomia, dysphagia and weight loss are the main long-term complications after CRT. The introduction of IMRT has reduced salivary gland damage, but xerostomia remains a common complication. After TORS, swallowing function tends to recover faster than after CRT. Speech therapy, swallowing rehabilitation and nutritional support should be integrated into the treatment plan.
9-valent HPV vaccination is the most effective means of preventing HPV-related oropharyngeal cancer, including tonsil cancer. Girls aged 12 are included in Korea's National Immunization Program, and expansion to boys is also recommended. The preventive effect is greatest when given before sexual debut. Smoking cessation and reduced drinking are key to preventing HPV-negative tonsil cancer, and smoking cessation is also important in HPV-positive tonsil cancer because smoking worsens prognosis. Safe sexual behavior (condom use, managing the number of partners) also contributes to reducing oral HPV transmission.
Visual examination of the oropharynx, including the tonsils, is performed at regular otolaryngology checkups (at least once a year). Unilateral tonsillar enlargement, sore throat persisting for more than 3 weeks, and a neck mass require prompt specialist referral. High-risk groups (smokers and drinkers, immunosuppressed patients) need intensive oropharyngeal surveillance.
Gillison ML, Chaturvedi AK, Anderson WF, Fakhry C. Epidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. Journal of Clinical Oncology. 2015;33(29):3235-3242. DOI: 10.1200/JCO.2015.61.6995
Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy (KEYNOTE-048). The Lancet. 2019;394(10212):1915-1928. DOI: 10.1016/S0140-6736(19)32591-7
Ferris RL, Blumenschein G Jr, Fayette J, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck (CheckMate 141). New England Journal of Medicine. 2016;375(19):1856-1867. DOI: 10.1056/NEJMoa1602252
Amin MB, Edge S, Greene F, et al. (eds). AJCC Cancer Staging Manual, 8th Edition. Springer. 2017. ISBN: 978-3-319-40617-6.
National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Head and Neck Cancers. Version 1.2026. NCCN. 2025. Available at: https://www.nccn.org
Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. The Lancet Oncology. 2010;11(8):781-789. DOI: 10.1016/S1470-2045(10)70017-6
Park JO, Joo YH, Jung CK, et al. Trends in Head and Neck Cancer in South Korea Between 1999 and 2012. JAMA Otolaryngology–Head & Neck Surgery. 2016;142(12):1157-1165. DOI: 10.1001/jamaoto.2016.2396
Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. Journal of the National Cancer Institute. 2008;100(4):261-269. DOI: 10.1093/jnci/djn011
Posner MR, Hershock DM, Blajman CR, et al. Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer (TAX 324). New England Journal of Medicine. 2007;357(17):1705-1715. DOI: 10.1056/NEJMoa070956
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022. CA: A Cancer Journal for Clinicians. 2024;74(3):229-263. DOI: 10.3322/caac.21834